HIV Infections
Conditions
Keywords
AIDS-Related Opportunistic Infections, Inosine Pranobex, Homosexuality, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Brief summary
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/or other conditions associated with ARC.
Interventions
DRUGInosine pranobex
Sponsors
Newport Pharmaceuticals International
Study design
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Exclusion criteria
Concurrent Medication: Excluded: * Cardiac glycosides. Patients with the following are excluded: * AIDS. * Presenting with chronic candida infection-colo/rectal, oral/pharyngeal, cutaneous (finger/toenails) - for = or \> 3 months who have not responded to therapy. * Critical illness. * Hemophilia. Prior Medication: Excluded within 1 month of study entry: * Steroids. * Cytotoxic immunosuppressive agents. * Radiotherapy and/or systemic antiviral medication. * Immunomodulators (including Isoprinosine). Prior Treatment: Excluded within 1 month of study entry: * Radiotherapy. History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction. * Lymphoid malignancy. Homosexual male patients with AIDS related complex (ARC). Current IV drug abuse.
Countries
United States
Outcome results
None listed